Improving HIV-related care through eHealth
Publication date: Available online 24 November 2019Source: The Lancet HIVAuthor(s): Guido E L van den Berk, M C Leoni, Georg M N Behrens, Jantjie Taljaard, Joop E Arends (Source: The Lancet HIV)
Source: The Lancet HIV - November 26, 2019 Category: Infectious Diseases Source Type: research
Risk compensation and STI incidence in PrEP programmes
Publication date: Available online 22 November 2019Source: The Lancet HIVAuthor(s): Matthew Quaife, Louis MacGregor, Jason J Ong, Mitzy Gafos, Sergio Torres-Rueda, Hannah Grant, Fern Terris-Prestholt, Peter Vickerman (Source: The Lancet HIV)
Source: The Lancet HIV - November 23, 2019 Category: Infectious Diseases Source Type: research
Are 96-week data enough for doravirine to DRIVE FORWARD?
Publication date: Available online 15 November 2019Source: The Lancet HIVAuthor(s): Christoph D Spinner, Tristan John Barber (Source: The Lancet HIV)
Source: The Lancet HIV - November 16, 2019 Category: Infectious Diseases Source Type: research
Efavirenz in pregnancy
Publication date: Available online 15 November 2019Source: The Lancet HIVAuthor(s): Stanzi Maria le Roux, Elaine J Abrams (Source: The Lancet HIV)
Source: The Lancet HIV - November 16, 2019 Category: Infectious Diseases Source Type: research
Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study
Publication date: Available online 15 November 2019Source: The Lancet HIVAuthor(s): Paige L Williams, Cenk Yildirim, Ellen G Chadwick, Russell B Van Dyke, Renee Smith, Katharine F Correia, Alexandria DiPerna, George R Seage, Rohan Hazra, Claudia S Crowell, Surveillance Monitoring for ART Toxicities (SMARTT) study of the Pediatric HIV/AIDS Cohort StudySummaryBackgroundPerinatal HIV transmission has substantially decreased with combination antiretroviral regimens, but complications in children who are HIV-exposed but uninfected, such as microcephaly, warrant ongoing surveillance. We aimed to evaluate whether individual in ut...
Source: The Lancet HIV - November 16, 2019 Category: Infectious Diseases Source Type: research
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
This study is registered with ClinicalTrials.gov, NCT02275780, and is closed to accrual.FindingsBetween Dec 1, 2014, and Oct 20, 2015, 1027 individuals were screened, of whom 769 participants were randomly assigned to doravirine (n=385) or ritonavir-boosted darunavir (n=384), and 383 in both groups were given at least one dose of their allocated treatment. Most participants were male (645 [84%] of 766) and white (560 [73%]), with a mean age of 35·2 years (SD 10·6). 292 participants in the doravirine group and 273 in the darunavir group completed 96 weeks of treatment. At week 96, a higher proportion of the doravirine gro...
Source: The Lancet HIV - November 16, 2019 Category: Infectious Diseases Source Type: research
Correction to Lancet HIV 2018; 5: e341
Publication date: Available online 12 November 2019Source: The Lancet HIVAuthor(s): (Source: The Lancet HIV)
Source: The Lancet HIV - November 13, 2019 Category: Infectious Diseases Source Type: research
Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial
Publication date: Available online 11 November 2019Source: The Lancet HIVAuthor(s): Alison D Grant, Salome Charalambous, Mpho Tlali, Aaron S Karat, Susan E Dorman, Christopher J Hoffmann, Suzanne Johnson, Anna Vassall, Gavin J Churchyard, Katherine L FieldingSummaryBackgroundTuberculosis, which is often undiagnosed, is the major cause of death among HIV-positive people. We aimed to test whether the use of a clinical algorithm enabling the initiation of empirical tuberculosis treatment by nurses in primary health-care clinics would reduce mortality compared with standard of care for adults with advanced HIV disease.MethodsI...
Source: The Lancet HIV - November 12, 2019 Category: Infectious Diseases Source Type: research
Empirical tuberculosis therapy in advanced HIV disease
Publication date: Available online 11 November 2019Source: The Lancet HIVAuthor(s): Yukari C Manabe, Mark W Tenforde (Source: The Lancet HIV)
Source: The Lancet HIV - November 12, 2019 Category: Infectious Diseases Source Type: research
Tackling stigma in the Welsh valleys
Publication date: Available online 11 November 2019Source: The Lancet HIVAuthor(s): Talha Burki (Source: The Lancet HIV)
Source: The Lancet HIV - November 12, 2019 Category: Infectious Diseases Source Type: research
New PrEP formulation approved…but only for some
Publication date: November 2019Source: The Lancet HIV, Volume 6, Issue 11Author(s): The Lancet HIV (Source: The Lancet HIV)
Source: The Lancet HIV - October 31, 2019 Category: Infectious Diseases Source Type: research
A complex epidemic prevents Peru reaching HIV goals
Publication date: November 2019Source: The Lancet HIV, Volume 6, Issue 11Author(s): Sophie Cousins (Source: The Lancet HIV)
Source: The Lancet HIV - October 31, 2019 Category: Infectious Diseases Source Type: research
Age-specific associations between HIV infection and carotid artery intima-media thickness in China: a cross-sectional evaluation of baseline data from the CHART cohort
Publication date: Available online 18 October 2019Source: The Lancet HIVAuthor(s): Haijiang Lin, Yingying Ding, Chenxi Ning, Xiaotong Qiao, Xiaochen Chen, Xiaoxiao Chen, Weiwei Shen, Xing Liu, Yuling Hong, Na HeSummaryBackgroundInconclusive results have been reported in studies evaluating the association between HIV infection and subclinical atherosclerosis. Unsolved issues include whether the increased atherosclerosis burden observed in some studies is attributed to greater prevalence of traditional risk factors or HIV infection. Therefore, we evaluated the association of HIV infection with subclinical atherosclerosis as ...
Source: The Lancet HIV - October 19, 2019 Category: Infectious Diseases Source Type: research
Time to change cardiovascular prevention in people with HIV
Publication date: Available online 18 October 2019Source: The Lancet HIVAuthor(s): Esteban Martinez (Source: The Lancet HIV)
Source: The Lancet HIV - October 19, 2019 Category: Infectious Diseases Source Type: research
HIV controllers: to treat or not to treat? Is that the right question?
Publication date: Available online 14 October 2019Source: The Lancet HIVAuthor(s): Nicolas Noël, Asier Saez-Cirion, Véronique Avettand-Fenoël, Faroudy Boufassa, Olivier LambotteSummaryThe term HIV controller refers to the small proportion of individuals infected with HIV who can spontaneously control viraemia to maintain very low viral loads. One major unresolved question is whether HIV controllers should receive antiretroviral therapy, given that international guidelines recommend treatment for all individuals who are infected with HIV. Differences in the definitions of a controller (in terms of the viral-load cutoff a...
Source: The Lancet HIV - October 15, 2019 Category: Infectious Diseases Source Type: research
